Increased TRPC3 expression in vascular endothelium of patients with malignant hypertension

Modern Pathology

Volumn 22, Issue 3, 2009, Pages 426-430

  Thilo, Florian ^a   Loddenkemper, Christoph ^a   Berg, Erika ^a   Zidek, Walter ^a   Tepel, Martin ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Malignant hypertension; Transient receptor potential channel; Vascular endothelium

Indexed keywords

TRANSIENT RECEPTOR POTENTIAL CHANNEL 3;

ADULT; ARTICLE; CONTROLLED STUDY; FEMALE; HEMOLYTIC UREMIC SYNDROME; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERTENSION; IMMUNOHISTOCHEMISTRY; KIDNEY BIOPSY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SYSTOLIC BLOOD PRESSURE; VASCULAR ENDOTHELIUM;

ADULT; ARTERIOLES; ENDOTHELIUM, VASCULAR; FEMALE; GENE EXPRESSION; HUMANS; HYPERTENSION, MALIGNANT; IMMUNOHISTOCHEMISTRY; KIDNEY; MALE; TRPC CATION CHANNELS;

EID: 61349089794     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2008.200     Document Type: Article

References (14)

1. Kitiyakara C, Guzman NJ. Malignant hypertension and hypertensive emergencies. J Am Soc Nephrol 1998;9:133-142.
2. van den Born BJ, Honnebier UP, Koopmans RP, et al. Microangiopathic hemolysis and renal failure in malignant hypertension. Hypertension 2005;45:246-251.
3. Liu D, Scholze A, Zhu Z, et al. Increased transient receptor potential channel TRPC3 expression in spontaneously hypertensive rats. Am J Hypertens 2005;18:1503-1507.
4. Dietrich A, Mederos Y, Schnitzler M, et al. Increased vascular smooth muscle contractility in TRPC6-/- mice. Mol Cell Biol 2005;25:6980-6989.
5. Liu D, Scholze A, Zhu Z, et al. Transient receptor potential channels in essential hypertension. J Hypertens 2006;24:1115-1124.
6. Liu DY, Thilo F, Scholze A, et al. Increased store-operated and 1-oleoyl-2-acetyl-sn-glycerol-induced calcium influx in monocytes is mediated by transient receptor potential canonical channels in human essential hypertension. J Hypertens 2007;25:799-808.
7. Thilo F, Scholze A, Liu DY, et al. Association of transient receptor potential canonical type 3 (TRPC3) channel transcripts with proinflammatory cytokines. Arch Biochem Biophys 2008;471:57-62.
8. Chandler WL, Jelacic S, Boster DR, et al. Prothrombotic coagulation abnormalities preceding the hemolytic-uremic syndrome. N Engl J Med 2002;346:23-32.
9. Tarr PI, Neill MA, Clausen CR, et al. Escherichia coli O157:H7 and the hemolytic uremic syndrome: importance of early cultures in establishing the etiology. J Infect Dis 1990;162:553-556.
10. Ruggenenti P, Noris M, Remuzzi G. Thrombotic microangiopathy, hemolytic uremic syndrome, and thrombotic thrombocytopenic purpura. Kidney Int 2001;60:831-846.
11. Shibagaki Y, Fujita T. Thrombotic microangiopathy in malignant hypertension and hemolytic uremic syndrome (HUS)/thrombotic thrombocytopenic purpura (TTP): can we differentiate one from the other? Hypertens Res 2005;28:89-95.
12. Fleming I, Busse R. Endothelium-derived epoxyeico-satrienoic acids and vascular function. Hypertension 2006;47:629-633.
13. Watanabe T, Kanome T, Miyazaki A, et al. Human urotensin II as a link between hypertension and coronary artery disease. Hypertens Res 2006;29:375-387.
14. Thijssen DH, Rongen GA, Smits P, et al. Physical (in)activity and endothelium-derived constricting factors: overlooked adaptations. J Physiol 2008;586:319-324.